- 著者
- 
             
             Hiroshi Inoue
             
             Ken Okumura
             
             Hirotsugu Atarashi
             
             Takeshi Yamashita
             
             Hideki Origasa
             
             Naoko Kumagai
             
             Masayuki Sakurai
             
             Yuichiro Kawamura
             
             Isao Kubota
             
             Kazuo Matsumoto
             
             Yoshiaki Kaneko
             
             Satoshi Ogawa
             
             Yoshifusa Aizawa
             
             Masaomi Chinushi
             
             Itsuo Kodama
             
             Eiichi Watanabe
             
             Yukihiro Koretsune
             
             Yuji Okuyama
             
             Akihiko Shimizu
             
             Osamu Igawa
             
             Shigenobu Bando
             
             Masahiko Fukatani
             
             Tetsunori Saikawa
             
             Akiko Chishaki
             
             on behalf of the J-RHYTHM Registry Investigators
             
          
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-13-0290,  (Released:2013-05-25)
- 参考文献数
- 24
- 被引用文献数
- 
             
             52
             
             
             110
             
             
          
        
        Background: Target anticoagulation levels for warfarin in Japanese patients with non-valvular atrial fibrillation (NVAF) are unclear. Methods and Results: Of 7,527 patients with NVAF, 1,002 did not receive warfarin (non-warfarin group), and the remaining patients receiving warfarin were divided into 5 groups based on their baseline international normalized ratio (INR) of prothrombin time (≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0). Patients were followed-up prospectively for 2 years. Primary endpoints were thromboembolic events (cerebral infarction, transient ischemic attack, and systemic embolism), and major hemorrhage requiring hospital admission. During the follow-up period, thromboembolic events occurred in 3.0% of non-warfarin group, but at lower frequencies in the warfarin groups (2.0, 1.3, 1.5, 0.6, and 1.8%/2 years for INR values of ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0059). Major hemorrhage occurred more frequently in warfarin groups (1.5, 1.8, 2.4, 3.3, and 4.1% for INR values ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0041) than in non-warfarin group (0.8%/2 years). These trends were maintained when the analyses were confined to patients aged ≥70 years. Conclusions: An INR of 1.6–2.6 is safe and effective at preventing thromboembolic events in patients with NVAF, particularly patients aged ≥70 years. An INR of 2.6–2.99 is also effective, but associated with a slightly increased risk in major hemorrhage. (UMIN Clinical Trials Registry UMIN000001569)